DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at William Blair boosted their Q4 2017 EPS estimates for shares of DexCom in a report released on Tuesday. William Blair analyst M. Kaczor now anticipates that the medical device company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.02. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.56) EPS.

Other equities research analysts have also recently issued reports about the company. Jefferies Group reissued a “buy” rating and issued a $91.00 target price on shares of DexCom in a research note on Thursday, September 28th. Canaccord Genuity reaffirmed a “buy” rating and set a $69.00 price objective (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Stephens reaffirmed a “buy” rating and set a $70.00 price objective (down from $83.00) on shares of DexCom in a research report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $87.00 price objective on shares of DexCom in a research report on Thursday, September 28th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $57.00 price objective (down from $85.00) on shares of DexCom in a research report on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $72.31.

Shares of DexCom (NASDAQ DXCM) opened at $56.75 on Thursday. DexCom has a 12 month low of $42.62 and a 12 month high of $88.80. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other news, Director Steven R. Altman bought 10,000 shares of the company’s stock in a transaction on Monday, November 6th. The shares were acquired at an average cost of $49.61 per share, with a total value of $496,100.00. Following the completion of the transaction, the director now owns 4,353 shares of the company’s stock, valued at approximately $215,952.33. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders sold 38,140 shares of company stock worth $2,158,576 over the last three months. Insiders own 1.70% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. FMR LLC boosted its position in DexCom by 9.9% in the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Janus Henderson Group PLC boosted its position in DexCom by 29.2% in the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after purchasing an additional 1,991,094 shares during the last quarter. Vanguard Group Inc. boosted its position in DexCom by 3.4% in the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after purchasing an additional 224,808 shares during the last quarter. BlackRock Inc. boosted its position in DexCom by 5.5% in the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after purchasing an additional 230,542 shares during the last quarter. Finally, Brown Advisory Inc. boosted its position in DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after purchasing an additional 1,515,134 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/01/13/dexcom-inc-dxcm-forecasted-to-post-q4-2017-earnings-of-0-06-per-share.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related stocks with our FREE daily email newsletter.